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Abstract 
 
This study evaluated the clinical utility and cost effectiveness of traditional MCS studies as decision tools in 
choosing antibiotics to treat infections in two tertiary hospitals in Northern Nigeria by retrospective evaluation of 
MCS records over six consecutive months. Of the 942 MCS studies that included 385(40.9%), 296(31.4%), 144 
(15.3%) 45 (4.8%) , 40 (4.3%), 26(3.1%) and 6(0.2%) urine, high vaginal swabs (HVS) , stool, sputum, pus, 
endocervical swabs (ECS)  and urethral swabs specimens performed, respectively on 510(54%) males and 432 (46%) 
females, only 9 (0.6%) had results that offered demonstrable influence on patients’ treatment at a cost effectiveness 
ratio of 4260.6 International dollars per 1. The estimated cost of MCS studies to the Nigerian economy (public health 
care provider) was 39.8million International dollars per annum. Our findings suggest that the traditional algorithm 
for decision on choice of antibiotic is not cost-effective. We proposed that empirical treatment based on community 
profiling of bacterial sensitivity to antibiotics may be superior. 
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Introduction 
 
              Traditionally, antibiotics are chosen empirically for a suspected infection based on the principle of 
background probability that, among others, frequently considers the most likely infective agent(s), its known 
sensitivity profile, availability of the antibiotic, allergy status of the patient, and cost. This choice is usually slated to 
be updated by the result of a microscopy-culture and sensitivity (MCS) study on an appropriate sample taken before 
initiating empirical therapy. Though this algorithm has come to be considered as standard of practice, it is probably 
based on clinical tradition and plausible biology rather than hard evidence of the utility of MCS studies. There are 
reasons to expect problems with MCS studies. MCS is an in vitro study which may not be transposable to the 
anticipated in vivo site of action of the antibiotics. When a positive culture is obtained, its clinical utility depends on 
the appropriateness of the sample, its quality, handling, transportation, laboratory technology, and technologist. 
These components may fail at any level. These suspicions have been supported by studies evaluating specific 
infectious illnesses. Several studies have questioned the usefulness of MCS in the management of patients with 
community-acquired pneumonia (García-Vázquez et al., 2004), respiratory infections (Ewig  et al., 2002), 
pyelonephritis (Wing et al., 2000; Thanassi, 1997), gonorrhea (Ghanem et al., 2004) and gynecological infections 
(Chandeying et al., 1998). Though some guidelines have cautiously tried to expunge routine MCS studies, it continues 
to be a tradition recommended by clinicians and policy makers (American Thoracic Society, 2001).To the best of our 
knowledge, no study has attempted to put a pan-establishment cost effectiveness profile to MCS studies. Such 
studies are necessary to guide clinical and policy decisions.  This study was therefore designed to address the 
primary questions of the clinical usefulness and cost-effectiveness of MCS study in clinical practice. 
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Methods 
 
           We collected retrospective laboratory paper records of consecutive cultures and sensitivity results from two 
tertiary centers in northwestern Nigeria for six months (1st January 2006 to 30th June 2006). The information of 
interest were hospital identity number (ID), sex, age, type of sample, presence or absence of bacterial growths and 
the antibiotic sensitivity results. We traced the patients’ files using hospital number and referral unit and reviewed 
the antibiotic treatment post MCS study result. We considered only MCS studies whose result either lead to a 
recorded change in pre-test antibiotic regimen or fit the pre-test antibiotic regimen and recorded by the clinician as 
having influenced clinical decision.  
            Data was analyzed using SYSTAT 12 software.  We analyzed MCS data with intention to treat which in this 
case refers to ‘intention to use’. It is thus assumed that all MCS studies were performed with an intention to use the 
result in decision making. Thus absence of record of use of MCS result, failure of patient to come back to collect the 
MCS result and failure of patients to come for follow up were all considered as failures. We calculated simple 
descriptive statistics of parameters of interest and derived the Odds and Risk ratios of all outcomes of MCS studies 
using SYSTAT 12 Software. We assumed presence or absence of bacterial growth (henceforth referred to only as 
‘growth’) to be independent and calculated the numbers needed to treat which we then translated as ‘numbers needed 
for growth’ (NNG) (i.e. any growth irrespective of type) and/or  ‘numbers needed for potential clinical impact’ ( i.e. 
any growth with associated sensitivity profile, because anecdotal evidence show that sensitivity profiles are not 
usually done for Candida albicans nor growths considered as normal flora) .  We also calculated the ‘numbers 
needed for demonstrated clinical impact’ (i.e. growths that resulted in a change of antibiotic or resulted in a decision 
to continue ongoing treatment regimen because of the growth) as additional measures of the clinical utility of MCS.  
**Numbers needed for growth (NNG) = reciprocal of the Risk ratios (RR) of growth 
= {RR (growth)-RR (no growth)}-1  
**Numbers needed for potential clinical impact= reciprocal of the Risk ratios of having a sensitivity result= {RR 
(growth with sensitivity result)-RR (growth without sensitivity result)}-1  
**Numbers needed for demonstrated clinical impact= reciprocal of the Risk ratios of using the result of sensitivity 
study in choosing an antibiotic= {RR (growth with sensitivity result)-RR (growth with sensitivity result that was used 
in treatment)}-1 
 
          We performed the cost effectiveness analysis as part of sectoral cost effectiveness (David et al., 2006; Pascalina 
et al., 2007) because we consider MCS to best fit allocation rather than technical efficiency. We evaluated the cost 
and health benefit of MCS alone with respect to the counterfactual case that it is not in place as an intervention( so 
called null scenario)(David et al., 2006) . We estimated costs using standard costing approach in economic 
evaluation (David et al., 2006; Pascalina et al., 2007). Costing was done from both providers’ and patients’ 
perspectives. Cost elements included were, personnel, materials, building space, administrative and equipment 
overheads on the one hand, then direct cash cost to patients. We designed and validated questionnaires which were 
then used to gather data from both primary and secondary sources. The purchase prices were used to derive 
discounted annual capital cost at a discount rate of 3% and life span of 5 years (Raymond et al., 2003). We collected 
salary data from staff members and computed labor costs by evaluating the time spent by each staff cadre in the 
process of performing an MCS (taking sample, transporting sample, laboratory processes etc) and multiplied this by 
the pro- rata earnings for each staff category.  The direct cash paid by the patient for service was estimated. We did 
not include costs incurred by patients (and accompanying persons) to access service and cost on lost time and 
potential earnings in lieu of interventions because it has been accepted that they are not reliably evaluated and are 
conjectural; they are often excluded from studies on ethical grounds(David et al., 2006; Pascalina et al.,  2007).  We 
determined the average cost of MCS in the Nigerian local currency (Naira) and determined its equivalent in 
International dollars (i.e. the amount of domestic currency that is of equivalent purchasing power as a dollar in the 
United State of America) (The World Bank, 2007) using the standardized conversion table (International Diabetic 
Association, 2007) because this has been shown to reflect more comparable cost statements (The World Bank, 2007). 
The average cost effectiveness ratio (ACER)( David et al., 2006; Pascalina et al.,  2007), defined as the total cost of all 
the MCS studies divided by the numbers of MCS studies with demonstrable contribution to clinical decision was 
then estimated. The sample studied was considered as the study population in its own right and therefore required 
neither confidence intervals nor median scores. This is because it is our opinion that it is intuitive that MCS studies 
would be highly variable both temporal and geometric within and between laboratories, and that this makes attempts 
at extrapolating inferences to all MCS as the study population ,as would be expected in classical data analysis, at best 
spurious. Furthermore, it is accepted that cost effectiveness has many uncertainties that cannot be captured by 
statistical confidence intervals (Pascalina et al., 2007).  
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Results 
 
                In the 6 months period reviewed, 942 MCS studies including 510(54%) on males and 432 (46%) on 
females were performed. Of the 942 MCS studies, 385 (40.9%), 296(31.4%), 144 (15.3%) 45 (4.8%), 40 (4.3%),  
 
Table 1:  Average utility of M/C/S studies  
 
MCS STUDIES 
 
NG 
 
NGPCI 
 
NGDCI 
Urine  3 175 104 
HVS  2 3 148 
Stool   4 13 72 
Sputum  9 9 45 
Pus  2 2 40 
ECS 1  1 Infinite 
Urethral  2 2 Infinite 
 
NG: Number of studies needed to get one study with a growth 
NGPCI: Number of studies needed to get one study with a growth that had potential clinical impact 
NGDCI: Number of studies needed to get one study with a growth that had demonstrable clinical impact 
 
 
 
Table 2: Average cost of conducting M/C/S per patient 
Item Number Cost Item Cost (Int. $) Percentage of Total Cost 
1 Consumable Materials 12.0 44.28 
2 Personnel 5.1 18.82 
3 Building Space 2.1 7.75 
4 Administrative and 
other  overheads 
1.5 5.54 
5 Equipment and building 2.4 8.86 
6 Cost to patient 4.00 14.76 
7 Average total cost per 
M/C/S 
27.1 100 
 
 
Table 3: Average cost effectiveness of M/C/S 
                                                    Cost of MCS Studies 
Cost In International Dollars 
Per study 
Average Cost effectiveness 
Ratio (ACER) in International 
dollars per study 
To health provider  23.1 2417.8 
To The Patient  4.0 418.7 
Total  27.1 4260.6* 
*ACER does not obey mathematical addition down a column because the denominator varies between provider and 
patient    
 
 
26 (3.1%) and 6 (0.2%) were on urine, high vaginal swabs (HVS), stool, sputum, pus, endocervical swabs (ECS) and 
urethral swabs, respectively.  Of the whole sample, 603 (64%) had no significant growth (Odds of no growth:  178: 
1), while 339(36%) had growth; (Odds of growth: 56: 1). The odds ratio of no growth to growth from the specimens 
was 3.2). Of the 339 cultures with growth, 37 (11%) provided no additional information of clinical relevance 
(Candiasis), and 302(89%) had sensitivity profiles. The Odd of no additional information of clinical relevance from 
MCS with growths was: 213: 1 and Odd of additional information of clinical relevance was 47: 1(Odds ratio of no 
additional information of clinical relevance to getting additional information of clinical relevance was 4.5). 
Only 9(0.6%) of the 942 MCS studies either fit the current treatment regimen or lead to a change in 
antibiotic therapy of the subjects. The Odd of an MCS being of clinical utility was 0.0097. Thirteen MCS studies 
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would have been performed to have 1 MCS with potential impact on clinical decision while 105 MCS studies were 
required to have 1 with demonstrable clinical impact. Of the 385 urine MCS, 314(81.3%) were on males, of which 
274 (87.3) were aged above 20 years and 40(12.7%) were all under 10 years. 71(18.7%) were on females, of which 
57(80.3%) were aged above 20 years, 7 (9.9%) were aged 14-20yrs and 7(9.9%) aged 13 years and below.   There 
was no growth in 269 (69.8%) samples while 116(30.2%) had growths.  
Fifty two (87.3%) of the female urine studies had no growth while 217(69.1%) of the male studies had no 
growth. The number of urine studies needed to obtain a growth was 1 in 3 but the number needed for demonstrable 
clinical impact was 1 in 104 in males and 1 in 71 in females (Table 1).  Of the 296 HVS MCS studies, 99 (33.4%) 
had no growth and 197(66.6%) had growth including Candida Albicans 33(16.7%), normal flora 60(30.5%) 
coliforms 104 (52.8%). The numbers needed for a growth was 1 in 2 studies, while the numbers needed to have a 
growth of potential clinical impact was 1 in 3 studies. The numbers needed for demonstrated clinical impact was 1 in 
148 studies.  Of the 26 ECS, 11(42.3%) had no growth and 15 (57.7%) had growth of which none contributed to 
clinical decision. Of the 144 stool studies, 110 (76.4%) had no growths and 34(23.6%) had growths. The number 
needed for a growth was 1 in 4, the number needed for a growth of potential clinical benefit was 1 in 13 and numbers 
needed for demonstrated clinical benefit was 1 in 72. Of the 45 sputum, 20(44.4%) had no growth and 25 (55.6%) 
had growth. The numbers needed for growth with demonstrated clinical impact was 1 in 45. Of the 40 pus studies 19 
(47.5%) had no growth and 21(52.5%) had growth. Numbers needed for growth and numbers needed for growth with 
potential clinical impact were both 1 in 2. Numbers needed for growth of demonstrable clinical impact was 1 in 40.  
Of the 6 urethral swabs, 2(33.3%) had no growth while 4 (66.7%) had growths. Numbers needed for growth and 
numbers needed for growth with potential clinical impact were both 1 in 2. In none of the growths was there 
demonstrable contribution to clinical decision.  
The average cost of one MCS was 23.1 International dollars to the provider and 4.0 International dollars to 
the patient. The ACER of MCS was 4,260.6 International dollars to 1.  Estimated annual cost of MCS was 51,127.6 
International dollars per hospital setting.  There is at least 1 General hospital per Local Government Council in 
Nigeria. The annual cost of MCS studies for the 774 councils in Nigeria was 39.8million International dollars. . Test 
specific ACER was 4,016.4 International dollars to 1 for HVS, 2,822.3 International dollars to 1 for Urine studies in 
males, 1,926.8 International dollars to 1 for urine studies in females, 1,953.9 International dollars to 1 for ECS, 
1,221.2 International dollars to 1 for sputum studies, 1,085.6 International dollars to 1 for pus studies and 
indeterminate for urethral swab.  
 
    
Discussion and Conclusion. 
 
MCS studies have been built and accepted ‘Volta face’ into traditional clinical protocol on the reasonable 
assumption that it would be of clinical utility. To the best of our knowledge, this study is the first one that has 
attempted to evaluate this assumption. There was no significant difference between number of males and females 
referred for MCS studies. The finding that the triad of urine, high vaginal and stool studies constitutes over 85% of 
MCS studies is expected in a third world setting where sexually transmitted and gastrointestinal infections are 
leading causes of morbidities and those with which clinicians may have higher concerns about antibiotic failures  
leading to a high rate of request for MCS. The finding that 64% of MCS studies had no bacterial growth should 
ordinarily suggest that, within the limits of bacteria like Mycoplasma and Chlamydia with special needs for culture, 
no bacterial infection exists at the site from which specimens were obtained, and probably suggests withdrawal of 
antibiotics. If so, clinical utility could be claimed. As it stands it remains that based on our intention to use model, 
64% of MCS studies have failed because absence of growth was not found to have been utilized to guide antibiotic 
usage.  
              That only 0.6% of MCS studies translated into decisions on antibiotic therapy appears incredulous but 
leading faculties in the study zone are not surprised as it fits into their overall general experience (Ekele BA, Legbo 
JN, Usmanu Danfodiyo University, personal communications). Given that clinicians would not be comfortable with 
choices made by tossing of a coin despite the odds of its outcome being 1 in 2 tosses, the 178:1 odd of not obtaining 
a growth from MCS is extremely discouraging. This observation is compounded by both the infinitesimal probability 
of 0.0097 that any MCS study is of clinical utility and that 105 MCS have to be performed for 1 study to have 
demonstrable clinical impact.  The wide gap between the number of MCS studies needed for one MCS to have 
potential impact on clinical decision (1 in 13) and numbers needed for demonstrable clinical impact (1 in 105) may 
suggest attrition in utility between laboratory output and clinicians but this finding needs further evidence based 
explanation. The results of the MCS-type specific analysis did not show significantly improved measures of clinical 
utility except for urine MCS in females that has a number needed for clinical utility of 1 in 71.  The ACER   of 
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4,260.6 International dollars for any-MCS study is discouraging. This study was not designed to compare test 
specific ACER and such comparison may not be valid post-hoc because comparative samples sizes were not used. 
What is the acceptable cost of a useful MCS study? If only 9 in 942 studies were clinically useful but saved life, 
would it be considered cost effective to expend 51,127.6 international dollars per annum to save at least 1 life?  Also, 
wouldn’t it be considered cost effective if one HVS study prevented pelvic infection, tubal blockage and infertility 
when compared against the cost of treating infertility?  Our data do not address these questions. The ACERs are, 
therefore, best taken as stand alone assessments. Given this, none of the MCS studies appear cost effective on face 
value.  
An alternative to MCS studies may be desirable. This study suggests that empirical antibiotic therapy based 
on literature-based listing of so called  ‘drugs –of –choice’ is probably successful, and perhaps more so than patient 
based MCS studies.  It, therefore, appears plausible that sensitivity profiling of bacterial species within defined 
geographical zones may outperform even literature based profiling. 
            An obvious shortcoming of this study is that the observations may only be true at the study points and that 
laboratory services may be on the weak side. If so, this study may then actually represent an audit that suggests 
system failure.  There is no evidence, beyond profiling of third world medical services, to support such a deduction. 
Moreover, MCS studies should be basic procedures in any tertiary centre. Studies in advanced countries showing 
yields of 2.8-5% on culture specimens supports our findings (Meropol  et al., 1997). There is no denying that a 
system analysis may be needed to find out the reason for the poor cost effectiveness parameters of MCS and 
subsequently correct them. However, it will still require re-evaluation to demonstrate that such changes do lead to 
improvement in performance. Even if the shortcomings are taken as true, the result of this study still emphasizes the 
need for systematic evaluation of clinical algorithms whose effectiveness appears obvious in order to obtain hard 
evidence that it is indeed so.  Given the huge cost implication, a repeat of similar assessment of MCS studies at all 
treatment points may be desirable with the aim of expunging it from clinical protocols if confirmed.  
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